Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

al.

"Fiscal 2008 was also an active and successful year for our Business Development group. In addition to the significant partnership completed with Teva, we also licensed rights outside of the United States for two of our core products. In April, we announced the licensing of European rights for VANTAS to Orion. VANTAS is pending final approval in Europe and it is expected to be launched by Orion in the first half of 2009. In May, we completed the license of Canadian rights for SANCTURA XR(TM) to Allergan.

"In addition, we successfully completed a $105 million non-recourse financing by monetizing a portion of the SANCTURA(R) franchise royalties. This non-recourse financing provides the Company sufficient capital to retire its outstanding Convertible Notes and to fund the Company into 2010. The Company now has the capital to get through several important milestones, including the expected FDA action date on NEBIDO, the results of our Phase III trial for octreotide, and the results of two Phase III trials for PRO 2000. In addition, we are optimistic that our ongoing discussions on the partnering front will contribute additional non-dilutive capital to the Company during the course of the coming year," concluded Dr. Cooper.

Recent Highlights

During the past year, the Company achieved a number of important milestones, including:

    Clinical Development
    -- Results From NEBIDO Phase III Trial Shows 94 Percent of Men Maintained
       Normal Testosterone Levels Throughout Treatment
    -- Results From Two-Year Study Confirming SUPPRELIN LA Implant Maintains
       Profound Suppression of Hormones in Children with Premature Onset
       Puberty
    -- Completion of Enrollment in Phase III Trial of PRO 2000
    -- Phase III Clinical Trial of Octreotide Implant for Acromegaly Initiated


    Business Development
    -- Licensing of European Rights for VANTAS to Orion C
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... 2015 Biovista Inc. freut ... von 2015 bekanntgeben zu können. Hierbei handelt es ... Biovista unterstützt mit seiner Möglichkeit der ... anderer Krankheiten als denen, für die ein Medikament ... sein Team bei der Wylder Nation Foundation bei ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Hanover Insurance Group, Inc. (NYSE: THG ... insurance products nationwide, announced today that it has ... equipment, orthotics and prosthetics sector -- which are ... (Logo: http://photos.prnewswire.com/prnh/20051031/NEM023LOGO) The new ...
... Tengion, Inc (NASDAQ: TNGN ), a leader in ... Chief Financial Officer of Tengion, will present at the upcoming ... 13, 2011, at 1:35 pm EDT. A ... of Events" in the Investors section of the Company,s website ...
... Sept. 7, 2011 MedWaves, AveCure™ microwave coagulation-ablation ... (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely ... over one-thousand patients worldwide, including lesions in bone, ... to bring its technology to treat lesions in ...
Cached Biology Technology:The Hanover Expands Innovative Solution for the Durable Medical Equipment, Orthotics and Prosthetics Market 2The Hanover Expands Innovative Solution for the Durable Medical Equipment, Orthotics and Prosthetics Market 3Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... options and pressures influence nearly every part of children,s ... a special supplement of the American Journal of Preventative ... at the University of Michigan, reveal that, in most ... soft drink bottling companies give students easy access to ...
... is one of two gene-hunting facilities in the nation ... to rigorously sort out how such environmental factors as ... genetic makeup to affect their risk for disorders as ... The Johns Hopkins Center for Inherited Disease ...
... HARBOR, N.Y. -- The first manual specifically geared ... Cold Spring Harbor Laboratory Press ( www.cshlpress.com ). ... from bioinformatics, technology, statistics, and biology, to provide a ... that are feasible for a wide range of laboratories. ...
Cached Biology News:Studies: Children obese due to a host of unhealthy pressures 2Studies: Children obese due to a host of unhealthy pressures 3Studies: Children obese due to a host of unhealthy pressures 4'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 2'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 3New book presents successful strategies for probing genetic variation 2New book presents successful strategies for probing genetic variation 3
... The pACHLT-A-BFP Baculovirus Transfer Vector is a derivative ... the gene for blue fluorescent protein (BFP), followed ... site (MCS).,Foreign genes are expressed as BFP-6xHis fusion ... restriction enzyme,sites (EcoR I, Stu I, Sac I, ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... pLivSelect is a direct antibiotic-based selection ... solely on colony survival, eliminating the need ... inexpensive process provides close to 100% accuracy ... ideal platform for robot colony picking. This ...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Biology Products: